Seiji Hoshi

11PUBLICATIONS
30CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyCancer cell biologyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 14, 2026
Sequential Enzalutamide-Docetaxel Versus Abiraterone-Docetaxel Therapy in Castration-Resistant Prostate Cancer: A Subanalysis of the ENABLE Study.

|Jul 02, 2026
The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.

|May 20, 2026
Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.

|Dec 30, 2025
Immunosuppressive Role of Integrin β8 in Recurrence After Bacillus Calmette-Guérin (BCG) Therapy for Non-Muscle Invasive Bladder Cancer.

Seiji Hoshi, Satoru Meguro, Syunta Makabe

|Aug 27, 2025
Targeting Senescence in Oncology: An Emerging Therapeutic Avenue for Cancer.

Satoru Meguro, Syunta Makabe, Kei Yaginuma

|Jul 29, 2025
[177Lu]Lu-PSMA-617 in Patients with Progressive PSMA+ mCRPC Treated With or Without Prior Taxane-Based Chemotherapy: A Phase 2, Open-Label, Single-Arm Trial in Japan.

Kouji Izumi, Ryuji Matsumoto, Yusuke Ito

Pageof 2

Frequent Collaborators

4 joint publications

Kanako Matsuoka

4 joint publications

Yuki Kato

4 joint publications

Noriyasu Kawai

3 joint publications

Junya Hata